BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15711261)

  • 1. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
    Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Grubb RL; Black A; Izmirlian G; Hickey TP; Pinsky PF; Mabie JE; Riley TL; Ragard LR; Prorok PC; Berg CD; Crawford ED; Church TR; Andriole GL;
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):748-51. PubMed ID: 19258472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.
    Shim HB; Lee SE; Park HK; Ku JH
    Prostate Cancer Prostatic Dis; 2007; 10(3):250-5. PubMed ID: 17297501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
    Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological diagnosis of prostate cancer in Korean men aged 70-79 years.
    Shim HB; Lee SE; Park HK; Ku JH
    Jpn J Clin Oncol; 2007 Oct; 37(10):782-7. PubMed ID: 17913831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
    Pinsky PF; Kramer BS; Crawford ED; Grubb RL; Urban DA; Andriole GL; Chia D; Levin DL; Gohagan JK
    Urology; 2006 Aug; 68(2):352-6. PubMed ID: 16904451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.